Boston Trust Walden Corp Has $70.13 Million Position in Teleflex Incorporated (NYSE:TFX)

Boston Trust Walden Corp boosted its holdings in shares of Teleflex Incorporated (NYSE:TFX) by 21.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 283,562 shares of the medical technology company’s stock after buying an additional 49,649 shares during the period. Boston Trust Walden Corp owned approximately 0.60% of Teleflex worth $70,131,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Cromwell Holdings LLC increased its position in shares of Teleflex by 59.0% during the third quarter. Cromwell Holdings LLC now owns 132 shares of the medical technology company’s stock worth $33,000 after acquiring an additional 49 shares in the last quarter. Canada Pension Plan Investment Board purchased a new stake in shares of Teleflex in the second quarter worth approximately $42,000. GAMMA Investing LLC lifted its holdings in shares of Teleflex by 131.1% in the third quarter. GAMMA Investing LLC now owns 171 shares of the medical technology company’s stock valued at $42,000 after purchasing an additional 97 shares in the last quarter. Versant Capital Management Inc boosted its position in shares of Teleflex by 20,700.0% during the second quarter. Versant Capital Management Inc now owns 208 shares of the medical technology company’s stock valued at $44,000 after buying an additional 207 shares during the last quarter. Finally, Blue Trust Inc. grew its holdings in Teleflex by 78.2% during the second quarter. Blue Trust Inc. now owns 212 shares of the medical technology company’s stock worth $48,000 after buying an additional 93 shares in the last quarter. 95.62% of the stock is owned by institutional investors.

Insider Activity

In related news, Director Stuart A. Randle sold 2,674 shares of the stock in a transaction dated Friday, August 16th. The stock was sold at an average price of $238.93, for a total transaction of $638,898.82. Following the sale, the director now owns 5,496 shares of the company’s stock, valued at approximately $1,313,159.28. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 1.43% of the stock is owned by company insiders.

Teleflex Stock Performance

NYSE TFX traded down $1.99 on Friday, hitting $233.63. 252,156 shares of the stock traded hands, compared to its average volume of 362,949. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.44 and a current ratio of 2.58. The firm has a market capitalization of $11.01 billion, a price-to-earnings ratio of 41.95, a PEG ratio of 2.15 and a beta of 1.16. Teleflex Incorporated has a 12 month low of $177.63 and a 12 month high of $257.85. The business’s fifty day moving average is $241.03 and its two-hundred day moving average is $223.68.

Teleflex (NYSE:TFX) last released its quarterly earnings data on Thursday, August 1st. The medical technology company reported $3.42 EPS for the quarter, beating the consensus estimate of $3.33 by $0.09. Teleflex had a net margin of 8.76% and a return on equity of 14.51%. The business had revenue of $749.70 million for the quarter, compared to the consensus estimate of $762.98 million. During the same period in the prior year, the firm earned $3.41 earnings per share. The company’s revenue was up .9% compared to the same quarter last year. As a group, equities analysts anticipate that Teleflex Incorporated will post 13.97 EPS for the current fiscal year.

Teleflex Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, September 16th. Shareholders of record on Thursday, August 15th were given a dividend of $0.34 per share. The ex-dividend date was Thursday, August 15th. This represents a $1.36 annualized dividend and a dividend yield of 0.58%. Teleflex’s dividend payout ratio is currently 24.42%.

Analyst Ratings Changes

Several brokerages have weighed in on TFX. Royal Bank of Canada raised their price objective on Teleflex from $260.00 to $275.00 and gave the company an “outperform” rating in a research note on Tuesday, October 8th. Truist Financial boosted their price target on shares of Teleflex from $247.00 to $255.00 and gave the stock a “hold” rating in a report on Monday, October 14th. Piper Sandler raised shares of Teleflex from a “neutral” rating to an “overweight” rating and lifted their target price for the stock from $205.00 to $245.00 in a research report on Monday, July 1st. Finally, Stephens boosted their target price on Teleflex from $275.00 to $290.00 and gave the stock an “overweight” rating in a research note on Friday, August 2nd. Three investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, Teleflex currently has a consensus rating of “Moderate Buy” and a consensus price target of $268.86.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.